Radiance Research AcademyInternational Journal of Current Research and Review2231-21960975-5241EnglishN2024January10Pharmaceutical SciencesEmulgel Towards Novel Formulation Development: A Comprehensive Review       English0106Eisha GanjuEnglish Susheel DeshmukhEnglish Bhaskar Kumar GuptaEnglish https://doi.org/10.31782/IJMPS.2024.14101Emulgels are an innovative topical drug delivery system that combines the properties of emulsions and gels to enhance the delivery and efficacy of pharmaceuticals. These systems leverage the advantages of both components: the solubilizing capabilities of emulsions and the stable, bioadhesive properties of gels. This review aims to summarize the development, formulation strategies, evaluation techniques, and therapeutic applications of emulgels. A comprehensive literature search was conducted across various scientific databases including PubMed, Scopus, and Web of Science. Studies focusing on the formulation, characterization, and clinical efficacy of emulgels were included. The review evaluates the methodologies used in the preparation of emulgels, including the choice of gelling agents, emulsifiers, and active pharmaceutical ingredients (APIs). Analytical techniques for assessing the physicochemical properties and stability of emulgels were also examined. The review identified key formulation parameters that influence the performance of emulgels, such as the type and concentration of gelling agents (e.g., carbomers, xanthan gum), emulsifiers (e.g., Tween, Span), and oils. Optimization of these components significantly affects the viscosity, spreadability, and drug release profile of emulgels. Studies demonstrated that emulgels exhibit improved drug penetration and sustained release compared to conventional topical formulations. Therapeutic applications of emulgels encompass a wide range of conditions including dermatological disorders, pain management, and microbial infections. The review also highlights novel advancements such as the incorporation of nanoparticles and the development of stimuli-responsive emulgels. Emulgels represent a promising platform for topical drug delivery, offering enhanced stability, bioavailability, and patient compliance. The versatility in their formulation allows for the incorporation of diverse APIs, making them suitable for various therapeutic areas. Future research should focus on the clinical translation of emulgels, exploring their potential in personalized medicine, and addressing regulatory challenges. Emulgels have the potential to revolutionize topical therapy and provide new avenues for effective and targeted drug delivery. EnglishEmulgel; Co-surfactant; Lipophilic; Gelling agent; Surfactant; bioavailabilityhttp://ijcrr.com/abstract.php?article_id=243http://ijcrr.com/article_html.php?did=2431. Ghosh PK, Majithiya RJ, Umrethia ML, Murthy RS. Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. AAPS PharmSci Tech. 2006;7(3): E172-E177 2. Kute S, Saudagar R. Emulsified gel: A novel approach for delivery of hydrophobic drugs: An overview. J Adv Pharm Educ Res. 2013;3(4):368-76. 3. Jain A, Deveda P, Vyas N, Chauhan J, Khambete H, Jain S. Development of antifungal emulsion based gel for topical fungal infection(s). Int J Pharm Res Dev. 2011;3(2):18-25. 4. Hussain A, Singh SK, Baboota S, Ali J, Kumar R, Prasad B. Formulation and optimization of nanoemulsion using antifungal lipid for topical delivery. Int J Biol Macromol. 2012;50(5):439- 49. 5. Emami J, Rezazadeh M, Sadeghi H, Varshosaz J. Formulation of a topical antifungal emulgel containing sertaconazole nitrate. Drug Dev Ind Pharm. 2016;42(4):544-51. 6. Bonacucina G, Martelli S, Palmieri GF. Rheological, mechanical and functional properties of topical preparations containing the synthetic polymeric emulsifier Pemulen™ TR-2. AAPS PharmSciTech. 2004;5(1):48-59. 7. Prajapati ST, Patel CG, Patel CN. Formulation and evaluation of topical aceclofenac gel using different gelling agent. Int J Pharm Pharm Sci. 2011;3(1):110-2. 8. Patel V, Patel RP, Bakshi V. Formulation development and evaluation of diclofenac sodium gel using aqueous microemulsion. Bull Pharm Res. 2012;2(3):122-8. 9. Bharadwaj S, Jain S, Choudhury A, Jha A, Dey A. Emulgel: A topical preparation for hydrophobic drugs. Pharm Innov J. 2015;4(5):13-6. 10. Pathan IB, Setty CM. Chemical penetration enhancers for transdermal drug delivery systems. Trop J Pharm Res. 2009;8(2):173-9. 11. Agrawal SS, Munjal P. Permeation studies of atenolol and metoprolol tartrate from three different polymer matrices for transdermal delivery. Indian J Pharm Sci. 2007;69(4):535-9. 12. Attia MA, El-Gibaly I, Shaltout SE, Fetih GN. Transdermal permeation and anti-inflammatory effect of piroxicam formulated in different formulae. Drug Dev Ind Pharm. 2004;30(2):245-56. 13. Chouksey R, Jain AK, Pandey H, Maithil A. Enhancement of bioavailability of aceclofenac by preparing microemulsion gel. Asian J Pharm Life Sci. 2012;2(2):151-60. 14. Mortazavi SA, Moghimi HR, Khosravi M, Aninaghi A, Farzaneh A. Preparation and evaluation of an emulgel containing propranolol hydrochloride for skin administration. Iran J Pharm Res. 2014;13:21-7. 15. Panchal JH, Patel PB, Patel RB, Bhimani BV. Formulation and evaluation of topical emulgel of mefenamic acid. J Pharm Sci Biosci Res. 2011;1(1):1-9. 16. Sintov AC, Botner S. Transdermal drug delivery using microemulsion and aqueous systems: influence of skin storage conditions on the in vitro permeability of diclofenac from aqueous vehicle systems. Int J Pharm. 2006;311(1-2):55-62. 17. Abdel-Mottaleb MM, Mortada ND, El Shamy AA, Awad GA. Preparation and evaluation of fluconazole topical gel. Int J Pharm Pharm Sci. 2012;4(5):176-83. 18. Vyas A, Kumar Sonker A, Pahwa R. Emulgel: A new approach to topical drug delivery. Int J Pharm Erudition. 2013;3(1):1-6. 19. Parmar VK, Patel HR, Bhimani BV, Bhatt NM, Patel CN. Emulgel: A topical preparation for hydrophobic drugs. Pharm Innov. 2013;2(4):50-63. 20. Khullar R, Kumar D, Seth N, Saini S. Formulation and evaluation of mefenamic acid emulgel for topical delivery. Saudi Pharm J. 2012;20(1):63-7. 21. Rachakonda VB, Basu B, Rao GY, Kumar AS, Sastry TP. Preparation and evaluation of diclofenac sodium emulgel for topical application. Indian J Pharm Educ Res. 2012;46(1):65-70. 22. Mohammad TK, Zakir MA, Riyaz AM. Formulation and evaluation of novel topical emulgel of clotrimazole for antifungal activity. Int J Pharm Biol Sci. 2013;4(1):33-43. 23. Dubey A, Prabhu P, Kamath JV. Formulation and evaluation of topical gel containing miconazole nitrate microsponges. Asian J Pharm Clin Res. 2013;6(4):168-72. 24. Sheth NS, Mistry RB. Formulation and evaluation of miconazole nitrate emulgel by quality by design approach. Int J Pharm Investig. 2013;3(3):164-71. 25. Khalil Y, Sakr A, Abd El-Razik A. Formulation and evaluation of silver sulfadiazine emulgel. Int J Pharm Pharm Sci. 2013;5(4):307-13. 26. Jain A, Gautam SP, Gupta Y, Khambete H, Jain S. Development and characterization of ketoconazole emulgel for topical drug delivery. Der Pharmacia Lettre. 2010;2(5):415-27. 27. Mirani AN, Patil MS. Formulation and evaluation of an emulgel of ibuprofen. Int J Pharm Life Sci. 2013;4(6):2698-705. 28. Singh M, Sharma S, Khokra SL, Saini V. Formulation and evaluation of topical emulgel of rofecoxib. Int J Pharm Pharm Sci. 2011;3(1):210-3. 29. Sahu GK, Nayak N, Mishra L. Formulation and in-vitro evaluation of carbopol 934 based modified emulgel of ketoprofen. Int J Pharm Res Bio Sci. 2012;1(5):65-76. 30. Osmani RA, Aloorkar NH, Kulkarni AS, Harkare BR, Bhosale RR. A novel approach for topical delivery of hydrophobic drugs: Emulgel. J Adv Pharm Sci. 2013;3(3):17-24. 31. Bhardwaj V, Tripathi P, Verma A. Topical emulgel: A review on various pharmaceutical approaches for improving its performance. J Pharm Sci Innov. 2013;2(5):1-6. 32. Pandey S, Goswami L, Rath B, Kumar A. Formulation and characterization of diclofenac sodium loaded nanoemulsion based emulgel. J Pharm Res. 2012;5(10):4898-904. 33. Shakeel F, Baboota S, Ahuja A, Ali J, Faisal MS, Shafiq S. Nanoemulsions as vehicles for transdermal delivery of aceclofenac. AAPS PharmSciTech. 2007;8(4). 34. Mate A, Ade P, Pise A, More S, Pise S, Kharwade R. Formulation and evaluation of polyherbal gel for the management of acne. Int J Curr Res Rev. 2021;13(4):117-22. 35. Baboota S, Shakeel F, Ahuja A, Ali J, Faisal MS, Shafiq S. Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib. Acta Pharm. 2007;57(3):315-32. 36. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv Drug Deliv Rev. 2004;56(5):619-58.

Radiance Research AcademyInternational Journal of Current Research and Review2231-21960975-5241EnglishN2024January10HealthcareRecent Progress in Alzheimer’s Disease: Pathophysiology, Newer Natural & Synthetic Inhibitors, and Therapeutic Targets       English0714Sweta ChandrolEnglish Sandeep GuptaEnglish Prashant TiwariEnglishMs. Sweta Chandrol, Research Scholar, Faculty of Pharmaceutical Sciences, Shri Shankaracharya Technical Campus, Bhilai 490020, Dist. Durg, Chhattisgarh, Indiahttps://doi.org/10.31782/IJMPS.2024.14102The inability to remember recent events, process new information, or complete even the most basic of tasks is a hallmark of Alzheimer’s disease, an irreversible neurodegenerative brain illness. Among those 65 and older, it is the leading cause of dementia. When a person’s cognitive and behavioural skills deteriorate to the point that they become a burden in everyday life, we say that they have dementia.There is currently no known way to halt the progression of AD or stop its symptoms from occurring. Huge literature survey was conducted from various popular medical databases such as Google Scholar, PubMed, ScienceDirect, etc. through the internet and the available data were classified according to their targets.The article focuses on basics of AD, History, Symptoms, Stages, Beta-amyloid peptide, Modulators of amyloid aggregation, Amyloid beta-oligomer, Targets for inhibiting the β-amyloid production (Monoclonal antibodies, Hormones, Inhibition of Aβ-peptide formation, Inhibition of Aβ-peptide formation [molecules like Posiphen, JNJ-54861911, LY3202626, E2609, AZD-3293, CNP520, MK-8931, LY2886721, and LY2811376],and Clearance of Aβ), and List of beta-amyloid inhibitors in clinical trials.This literature evidences may be a convenient reference (particularly, the low molecular-weight inhibitors) to the modern-day researchers (pharmacognosists, pharmacologists, clinicians, medicinal chemists, medical practitioners, scientists, etc.) working dedicatedly in AD research.This study will certainly open novel avenues for ligand development and revolutionary applications in pharmacotherapeutics. EnglishAlzheimer’s disease, Beta-Amyloid, Tau protein, Cholinesterase, Inhibitors, Clinical trialshttp://ijcrr.com/abstract.php?article_id=244http://ijcrr.com/article_html.php?did=2441. Kowall NW, Budson AE. The handbook of Alzheimer’s disease and other dementias. John Wiley & Sons; 2011. 2. Taylor R. Alzheimer’s from the inside out. Health Professions Press; 2007. 3. Morrison AS, Lyketsos C. The pathophysiology of Alzheimer’s disease and directions in treatment. Adv Stud Nurs. 2005;3(8):256-70. 4. Alzheimer A. Uber eineeigenartigeErkrankung der Hirnrinde. ZentralblNervenh Psych. 1907;18:177-9. 5. Bondi MW, Edmonds EC, Salmon DP. Alzheimer’s disease: past, present, and future. J Int Neuropsychol Soc. 2017;23(9- 10):818-31. 6. Munoz DG, Feldman H. Causes of Alzheimer’s disease. Can Med Assoc J. 2000;162(1):65-72. 7. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol. 1991;82(4):239-59. 8. Gómez?Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol. 1997;41(1):17-24. 9. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurol. 1998;50(1):136-45. 10. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dement Geriatr Cogn Disord. 1996;7(6):293-303. 11. Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120(3):885-90. 12. Defelice FG, Ferreira ST. Physiopathological modulators of amyloid aggregation and novel pharmacological approaches in Alzheimer’s disease. An Acad Bras Ciênc. 2002;74(2):265-84. 13. Verbeek MM, Ruiter DJ, De Waal RM. The Role of Amyloid in the Pathogenesis of Alzheimers’s Disease. Biol Chem. 1997;378:937-50. 14. Sandbrink R, Hartmann T, Masters CL, Beyreuther K. Genes contributing to Alzheimer’s disease. Mol Psychiatry. 1996;1(1):27-40. 15. Campbell A. The potential role of aluminium in Alzheimer’s disease. Nephrol Dial Transplant. 2002;17(2):17-20. 16. Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, et al. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and β-amyloid in the aging brain. J Neuro Sci. 2005;25(4):823-9. 17. Shih RA, Hu H, Weisskopf MG, Schwartz BS. Cumulative lead dose and cognitive function in adults: a review of studies that measured both blood lead and bone lead. Environ Health Perspect. 2007;115(3):483-92. 18. Baum L, Chan IH, Cheung SK, Goggins WB, Mok V, Lam L, et al. Serum zinc is decreased in Alzheimer’s disease and serum arsenic correlates positively with cognitive ability. Biometals. 2010;23(1):173-9. 19. Singh NK, Chhillar N, Banerjee BD, Bala K, Basu M, Mustafa M. Organochlorine pesticide levels and risk of Alzheimer’s disease in north Indian population. Human Exptoxicol. 2013;32(1):24-30. 20. Kamel F, Hoppin JA. Association of pesticide exposure with neurologic dysfunction and disease. Environ Health Perspect. 2004;112(9):950-8. 21. Baldi I, Lebailly P, Mohammed-Brahim B, Letenneur L, Dartigues JF, Brochard P. Neurodegenerative diseases and exposure to pesticides in the elderly. Am J Epidemiol. 2003;157(5):409-14. 22. Yegambaram M, Manivannan B, G Beach T, U Halden R. Role of environmental contaminants in the etiology of Alzheimer’s disease: A review. Curr Alzheimer Res. 2015;12(2):116-46. 23. Viberg H, Fredriksson A, Eriksson P. Neonatal exposure to polybrominated diphenyl ether (PBDE 153) disrupts spontaneous behaviour, impairs learning and memory, and decreases hippocampal cholinergic receptors in adult mice. Toxicol Appl Pharmacol. 2003;192(2):95-106. 24. Kim SH, Knight EM, Saunders EL, Cuevas AK, Popovech M, Chen LC, et al. Rapid doubling of Alzheimer’s amyloid-β40 and 42 levels in brains of mice exposed to a nickel nanoparticle model of air pollution. F1000Res. 2012;1:70. 25. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer’s disease. In: Apolipoprotein E and Alzheimer’s Disease 1996 (pp. 103-125). Springer, Berlin, Heidelberg. 26. Crowther RA. Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proc Natl Acad Sci. 1991;88(6):2288-92. 27. Kidd M. Paired helical filaments in electron microscopy of Alzheimer’s disease. Nature. 1963;197(4863):192-3. 28. Wischik CM, Crowther RA, Stewart M, Roth M. Subunit structure of paired helical filaments in Alzheimer’s disease. J Cell Biol. 1985;100(6):1905-12. 29. Crowther RA, Wischik CM. Image reconstruction of the Alzheimer paired helical filament. EMBO J. 1985;4(13B):3661-5. 30. Wischik CM, Novak M, Thøgersen HC, Edwards PC, Runswick MJ, Jakes R, et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci. 1988;85(12):4506-10. 31. Wischik CM, Novak M, Edwards PC, Klug A, Tichelaar W, Crowther RA. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci. 1988;85(13):4884-8. 32. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl  Acad Sci. 1975;72(5):1858-62. 33. Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev. 2000;33(1):95-130. 34. Neve RL, Harris P, Kosik KS, Kurnit DM, Donlon TA. Identification of cDNA clones for the human microtubuleassociated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Mol Brain Res. 1986;1(3):271-80. 35. Andreadis A, Broderick JA, Kosik KS. Relative exon affinities and suboptimal splice site signals lead to non-equivalence of two cassette exons. Nucleic Acids Res. 1995;23(17):3585-93. 36. Andreadis A, Brown WM, Kosik KS. Structure and novel exons of the human tau gene. Biochem. 1992;31(43):10626-33. 37. Himmler A, Drechsel D, Kirschner MW, Martin DW. Tau consists of a set of proteins with repeated C-terminal microtubulebinding domains and variable N-terminal domains. Mol Cell Biol. 1989;9(4):1381-8. 38. Nelson PT, Stefansson K, Gulcher J, Saper CB. Molecular evolution of τ protein: implications for Alzheimer’s disease. J Neurochem. 1996;67(4):1622-32. 39. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron. 1989;3(4):519-26. 40. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule?associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 1989;8(2):393-9. 41. Sawa A, Oyama F, Matsushita M, Ihara Y. Molecular diversity at the carboxyl terminus of human and rat tau. Mol Brain Res. 1994;27(1):111-7. 42. Kosik KS, Orecchio LD, Bakalis S, Neve RL. Developmentally regulated expression of specific tau sequences. Neuron. 1989;2(4):1389-97. 43. Coyle JT, Price DL, Delong MR. Alzheimer’s disease: a disorder of cortical cholinergic Innervation. Sci. 1983;219(4589):1184- 90. 44. Kosik KS, Kowall NW, McKee A. Along the way to a neurofibrillary tangle: a look at the structure of tau. Ann Med. 1989;21(2):109-12. 45. Goedert M, Jakes R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J. 1990;9(13):4225-30. 46. Brandt R, Léger J, Lee G. Interaction of tau with the neural plasma membrane mediated by tau’s amino-terminal projection domain. J Cell Biol. 1995;131(5):1327-40. 47. Hirokawa N, Shiomura Y, Okabe S. Tau proteins: the molecular structure and mode of binding on microtubules. J Cell Biol. 1988;107(4):1449-59. 48. Danao K, Kodape Y, Mahapatra D, Borikar S, Karande N. Highlights on Synthetic, Natural, and Hybrid Cholinesterase Inhibitors for Effective Treatment of Alzheimer’s Disease: A Review. Int J Cur Res Rev. 2021;13(11):27-34. 49. Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K. Alzheimer’s disease drug development pipeline: 2017. Alzheimers Dement. 2017;3(3):367-84. 50. Cummings J, Lee G, Ritter A, Zhong K. Alzheimer’s disease drug development pipeline: 2018. Alzheimers Dement. 2018;4:195-214. 51. Weller J, Budson A. Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Res. 2018;7:1161. 52. Cummings J, Blennow K, Johnson K, Keeley M, Bateman RJ, Molinuevo JL et al. Anti-tau trials for Alzheimer’s disease: a report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis. 2019;6(3):157-63. 53. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement. 2019;5:272-93. 54. Bauzon J, Lee G, Cummings J. Repurposed agents in the Alzheimer’s disease drug development pipeline. Alzheimers Res Ther. 2020;12(1):1-6. 55. Khoury R, Patel K, Gold J, Hinds S, Grossberg GT. Recent progress in the pharmacotherapy of Alzheimer’s disease. Drugs Aging. 2017;34(11):811-20.